Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

The advent of effective antiretroviral therapy (ART) has increased the lifespan of many people living with HIV. As a result, ...

In his Tuesday address to Congress, President Trump listed U.S.-funded programs that he considers an "appalling waste" — ...

Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...

Philadelphia announced in 2020 that the city would be participating in an initiative to “end” the HIV epidemic by reducing ...

New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and ...

Almost half of women in Africa will be obese or overweight by 2030, according to a new study, an "alarming rise" that has ...

Lynae Darbes, PhD, presented research on the effectiveness of a home-based intervention for HIV prevention among couples ...

Incident HCV infection more than doubled among HIV-positive MSM with no history of injection drug use between 1995 and 2023.

Cabotegravir was found to prevent HIV acquisition as a monotherapy pre-exposure prophylaxis (PrEP) and to treat HIV as a ...

Disparities in HIV diagnosis rates were observed between Black and White individuals in the US from 2017 to 2021.